Pacific Biosciences of California Inc (PACB) Prix

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 485 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.